Plasma-SeqSensei™ Thyroid Cancer RUO Kit

The Plasma-SeqSensei™ (PSS) Thyroid Cancer RUO (research use only) Kit detects mutations in circulating tumour DNA (ctDNA) from plasma in patients with thyroid cancer.

The kit uses next generation sequencing and covers the BRAF and NRAS genes with hotspot mutations:. These gene mutations are associated with more rapid cancer growth and worse prognosis. [1-2]

Differentiated (papillary (PTC) and follicular TC (FTC)) make up more than 90% of thyroid malignancies (BRAF with >60% and NRAS with 6-57% frequency of known somatic mutations). [3]

For the configuration of the Plasma-SeqSensei™ Thyroid RUO kits, two key cancer genes were selected after comparison of mutation frequencies using the COSMIC (Catalogue of Somatic Mutation in Cancer) and cBioPortal for cancer genomics databases.

Feature

• Highly sensitive <0.07 % MAF
• Able to detect 7 MM with 95 % confidence across all mutations (absolute quantification)
• High flexibility of between 2 - 16 samples/run
• Fast TAT (2 days)
• Convenient software

References

Huang et al. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagnostic Pathology 14(74), 1-10, 2019.

Perdana et al. Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital. Asian Pac J Cancer Prev 21(11), 3267-3277, 2020.

Prete et al. Update on Fundamental Mechanisms of Thyroid Cancer. Frontiers in Endocrinology 11(102), 1-10, 2020.

https://cancer.sanger.ac.uk/cosmic

https://www.cbioportal.org/